| Genesis Minerals Limited (GMD) ORDINARY FULLY PAID |
Materials |
$7,699 |
Quarterly Activities Report - December 2025
|
29 Jan 2026 9:19AM |
$8.130 |
$6.740 |
fallen by
17.10%
|
|
GMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Record gold production of 74,261 ounces at A$2,635/oz.
- ASPIRE 400 strategy aims to accelerate growth.
- Tower Hill project development ahead of schedule.
- Cash position at A$342 million with no corporate debt.
- Net profit after tax between A$235 million and A$245 million.
- Sustainability efforts include agreements with traditional owners.
- Major agreements to shorten Leonora rail line for mill expansion.
- FY26 growth capital outlook increased to A$220-240 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sylvania Resources Limited (SLV) ORDINARY FULLY PAID |
Materials |
$225 |
PDS dated 13 January 2026
|
29 Jan 2026 9:19AM |
$0.745 |
$0.745 |
fallen by
0%
|
|
| Beam Communications Holdings Limited (BCC) ORDINARY FULLY PAID |
Information Technology |
$16 |
BCC December 2025 Quarterly Activities Report & Appendix 4C
|
29 Jan 2026 9:19AM |
$0.155 |
$0.190 |
risen by
22.58%
|
|
BCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Healthy cash position with $4 million in available funds, increasing by US$9 million from Zoleo Inc. divestment.
- Legacy businesses generated a positive adjusted free cash flow of $0.3 million.
- Strong cost control countered expected revenue drops due to Zoleo divestment.
- Anticipated positive free adjusted cash flows for FY26.
- Quarterly revenue declined to $3.3 million due to the absence of ZOLEO device orders.
- Core equipment business revenue fell 41.1% and SatPhone Shop revenue dropped 20.8% compared to PCP.
- Recurring revenue from Airtime Services increased by 17.4%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Critical Resources Limited (CRR) ORDINARY FULLY PAID |
Materials |
$26 |
Proposed issue of securities - CRR
|
29 Jan 2026 9:18AM |
$0.010 |
$0.008 |
fallen by
20%
|
|
| Critical Resources Limited (CRR) ORDINARY FULLY PAID |
Materials |
$26 |
Critical Resources Secures $1.75M Placement
|
29 Jan 2026 9:18AM |
$0.010 |
$0.008 |
fallen by
20%
|
|
CRR - Price-sensitive ASX Announcement
Full Release
Key Points
- Critical Resources Limited secured $1.75 million through a placement.
- 175 million ordinary shares issued at $0.01 each.
- 1-for-4 attaching options exercisable at $0.008, expiring 23 April 2028.
- Funds to advance Mavis Lake Lithium Project, gold and antimony exploration, and lithium-ion battery program.
- Placement completed at no discount to the last share price.
- Board and management invested $250,000, pending shareholder approval.
- 62 Capital Pty Ltd acted as Sole Lead Manager.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Biotron Limited (BIT) ORDINARY FULLY PAID |
Health Care |
$7 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jan 2026 9:18AM |
$0.004 |
$0.003 |
fallen by
37.50%
|
|
BIT - Price-sensitive ASX Announcement
Full Release
Key Points
- Acquisition of Sedarex Limited and $2.5M capital raising.
- Completion of a two-tranche Placement raising $1 million.
- Completion of an Entitlement offer raising $645,861.
- BIT-HBV001 showed superior anti-HBV activity compared to Tenofovir.
- Patent application filed for BIT-HBV001.
- Research and development expenses totaled $100,000; staff costs were $166,000.
- Cash equivalents at the end of the period were $1,643,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$616 |
December 2025 Quarterly Activity Report and Appendix 4C
|
29 Jan 2026 9:17AM |
$2.420 |
$3.370 |
risen by
39.26%
|
|
RAC - Price-sensitive ASX Announcement
Full Release
Key Points
- Racura Oncology Ltd released its December 2025 Quarterly Activity Report and Appendix 4C.
- Racura announced the discovery of the primary mechanism of action of (E,E)-bisantrene, an important anticancer agent.
- The company's lead asset, RCDS1, primarily functions by binding to G4-DNA & RNA structures.
- Racura announced new clinical programs in mutant epidermal growth factor receptor non-small cell lung cancer and acute myeloid leukaemia.
- Racura underwent a name change from Race Oncology Limited to Racura Oncology Ltd.
- The company raised $3.22 million through a private placement and held a strong cash balance of $20.94 million as of 31 December 2025.
- Racura received significant R&D Tax Incentive funding from the Australian Taxation Office.
- The company engaged Beyond Drug Development to support the HARNESS-1 Phase 1a/b clinical trial.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PhosCo Ltd (PHO) ORDINARY FULLY PAID |
Materials |
$60 |
Investor Update Presentation - January 2026
|
29 Jan 2026 9:16AM |
$0.145 |
$0.115 |
fallen by
20.69%
|
|
| Grand Gulf Energy Limited (GGE) ORDINARY FULLY PAID |
Energy |
$12 |
Trading Halt
|
29 Jan 2026 9:16AM |
$0.002 |
$0.004 |
risen by
100%
|
|
GGE - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Grand Gulf Energy Limited (ASX: GGE).
- Pending announcement on exploration rights and capital raising.
- Trading halt effective until 2 February 2026 or announcement release.
- Company focuses on helium exploration in North America.
- Grand Gulf Energy's Red Helium project is located in Utah's Paradox Basin.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| First Au Limited (FAU) ORDINARY FULLY PAID |
Materials |
$39 |
Trading Halt
|
29 Jan 2026 9:15AM |
$0.011 |
$0.012 |
risen by
4.55%
|
|
FAU - Price-sensitive ASX Announcement
Full Release
Key Points
- FAU requests a trading halt pending announcements.
- Trading halt is until 2 February 2026 or announcement release.
- FAU is awaiting drilling results and a capital raising announcement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genesis Minerals Limited (GMD) ORDINARY FULLY PAID |
Materials |
$7,699 |
Board and Management restructure
|
29 Jan 2026 9:14AM |
$8.130 |
$6.740 |
fallen by
17.10%
|
|
GMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Raleigh Finlayson appointed Executive Chair to focus on growth and leadership.
- Matthew Nixon promoted to CEO to oversee daily operations and execute the growth plan.
- Duncan Coutts transitions to Executive Director - Operations for operational oversight.
- Tony Kiernan becomes Lead Independent Director focusing on corporate governance.
- The restructure aims to support Genesis Minerals' rapid growth and operational excellence.
- Genesis Minerals is now an ASX100 company, highlighting its successful expansion.
- New roles effective immediately to strengthen management team for upcoming projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Adavale Resources Limited (ADD) ORDINARY FULLY PAID |
Materials |
$18 |
Trading Halt
|
29 Jan 2026 9:13AM |
$0.056 |
$0.053 |
fallen by
5.36%
|
|
ADD - Price-sensitive ASX Announcement
Full Release
Key Points
- Adavale Resources Limited requested a trading halt.
- The halt is pending an announcement about a capital raising.
- The halt will last until 2 February 2026 or the announcement release.
- The company is unaware of reasons against the trading halt.
- No further information is necessary to inform the market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$31 |
Investor Webinar Presentation - Q2 FY26
|
29 Jan 2026 9:13AM |
$0.079 |
$0.064 |
fallen by
18.99%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- CurveBeam AI received purchase orders for five devices in Q2 FY26.
- A $4.0 million milestone investment was triggered and is pending final receipt.
- Regulatory engagement for HiRise™ in China is advancing with WEGO Orthopaedics.
- FDA 510(k) application submitted for BMD module, clearance targeted for mid-CY26.
- HiRise™ project for robotic-aided surgical systems is progressing.
- Cash balance reported at A$8.03 million including pending WEGO payment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$31 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jan 2026 9:12AM |
$0.079 |
$0.064 |
fallen by
18.99%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- CurveBeam AI received five purchase orders, including four HiRise™ and one LineUp device.
- The company progressed its agreement with Shandong WEGO Orthopaedics, triggering a $4.0 million investment.
- FDA 510(k) application submitted for the BMD module, with clearance expected by mid-2026.
- Net cash used in operations was A$2.15 million, depicting improvement from the previous quarter.
- Equity financing added A$4.03 million, with R&D tax rebate received.
- Enhanced validation efforts for HiRise™ system compatibility with robotic surgery systems.
- Significant promotional activities for HiRise™ initiated in China under NMPA registration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arafura Rare Earths Ltd (ARU) ORDINARY FULLY PAID |
Materials |
$1,451 |
Quarterly Activities and Appendix 5B
|
29 Jan 2026 9:12AM |
$0.265 |
$0.310 |
risen by
16.98%
|
|
ARU - Price-sensitive ASX Announcement
Full Release
Key Points
- Arafura Rare Earths Ltd progressed its Greenhouse Gas Emissions Reduction Pathway, aiming for net zero by 2050.
- The company is exploring the use of concentrated solar thermal for steam generation to reduce emissions.
- Local stakeholder engagement continues, including meetings with Traditional Owners and local service providers.
- Meetings with government officials emphasize support for the Nolans Project.
- Arafura has secured significant equity funding, including a US$300 million non-binding interest from US EXIM.
- Cash position improved significantly to A$571 million by the end of 2025.
- The company is advancing its Local and Indigenous Workforce Development Program.
- Environmental management includes the refinement of systems to align with regulatory and operational requirements.
- Exploration activities at Nolans Bore focused on mining-related studies.
- The NdPr market experienced price increases due to global trade tensions and supply chain vulnerabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$94 |
ALA's IND FOR ALA-101 ACCEPTED BY THE U.S.FDA
|
29 Jan 2026 9:11AM |
$0.088 |
$0.078 |
fallen by
11.36%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- U.S. FDA accepted IND application for ALA-101.
- Enables first-in-human clinical trials for CD19-positive NHL and leukemia.
- Regulatory validation de-risking Arovella's clinical development plan.
- ALA-101 is engineered with CAR19-iNKT cells for scalable 'off-the-shelf' dosing.
- The IND acceptance provides a framework for future CAR-iNKT cell programs.
- Will conduct phase 1 trial in Australia via CTN scheme.
- Anticipates expanding development for other solid tumor products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austral Resources Australia Ltd (AR1) ORDINARY FULLY PAID |
Materials |
$200 |
Site Visit Presentation
|
29 Jan 2026 9:11AM |
$0.120 |
$0.080 |
fallen by
33.33%
|
|
| Viking Mines Limited (VKA) ORDINARY FULLY PAID |
Materials |
$36 |
VKA TO COMMENCE HIGH-RESOLUTION GEOPHYSICS AT LINKA PROJECT
|
29 Jan 2026 9:10AM |
$0.012 |
$0.015 |
risen by
25%
|
|
| Peak Processing Limited (PKP) ORDINARY FULLY PAID |
Health Care |
$20 |
Trading Halt
|
29 Jan 2026 9:10AM |
$0.019 |
$0.017 |
fallen by
10.53%
|
|
PKP - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Peak Processing Limited (PKP).
- Trading halt related to a proposed capital raise.
- Halt will last until 2 February 2026 or announcement release.
- Necessary for managing continuous disclosure obligations.
- Expected announcement before normal trading on 2 February 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rhythm Biosciences Limited (RHY) ORDINARY FULLY PAID |
Health Care |
$62 |
Rhythm Biosciences secures strategic alliance with AGRF
|
29 Jan 2026 9:09AM |
$0.150 |
$0.175 |
risen by
16.67%
|
|
| Diablo Resources Limited (DBO) ORDINARY FULLY PAID |
Materials |
$4 |
Appendix 5B - Quarterly Cash Flow Report
|
29 Jan 2026 9:09AM |
$0.030 |
$0.015 |
fallen by
50%
|
|
DBO - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Cash Flow Report
- Cash flows for the quarter ending 31 December 2025
- Steps for raising further cash are planned
- Board confident in successful fundraising
- Compliance with ASX Listing Rules and Australian Accounting Standards
- Report authorised by the Board of Directors
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Venus Metals Corporation Limited (VMC) ORDINARY FULLY PAID |
Materials |
$46 |
Strategic Review and Appointment of Financial Advisor
|
29 Jan 2026 9:08AM |
$0.215 |
$0.235 |
risen by
9.30%
|
|
| Diablo Resources Limited (DBO) ORDINARY FULLY PAID |
Materials |
$4 |
Quarterly Activities Report
|
29 Jan 2026 9:08AM |
$0.030 |
$0.015 |
fallen by
50%
|
|
DBO - Price-sensitive ASX Announcement
Full Release
Key Points
- Star Range Silver-Antimony Project saw 186 claims staked covering 14.5km².
- Initial sampling returned high-grade silver and antimony results.
- Drone aeromagnetic survey completed with results expected in Q1 2026.
- Phoenix Copper Project's maiden drill program revealed promising copper results.
- Matthew Blumberg joined as a Non-Executive Director.
- Diablo held $943,000 in cash at quarter-end.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Woolworths Group Limited (WOW) ORDINARY FULLY PAID |
Consumer Staple |
$45,798 |
Woolworths Group Board update
|
29 Jan 2026 9:08AM |
$30.410 |
$37.490 |
risen by
23.28%
|
|
| New Age Exploration Limited (NAE) ORDINARY FULLY PAID |
Energy |
$9 |
Drill Program Completed at Wagyu Gold Pilbara
|
29 Jan 2026 9:07AM |
$0.003 |
$0.002 |
fallen by
33.33%
|
|
NAE - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of 40 RC drill holes totaling 4,034 meters at the Wagyu Gold Project.
- Targeted high-grade gold extensions associated with Hemi-style intrusives.
- Drill samples sent to Intertek Laboratories in Perth with results expected in February and March 2026.
- The Wagyu Gold Project is located near the 11.2Moz Hemi Gold Deposit.
- Visual geological observations suggest the presence of intrusive lithologies and alterations.
- NAE Executive Director highlighted the significance of the program in understanding the intrusive system.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
